Multi‐criteria manufacturability indices for ranking high‐concentration monoclonal antibody formulations

The need for high‐concentration formulations for subcutaneous delivery of therapeutic monoclonal antibodies (mAbs) can present manufacturability challenges for the final ultrafiltration/diafiltration (UF/DF) step. Viscosity levels and the propensity to aggregate are key considerations for high‐concentration formulations. This work presents novel frameworks for deriving a set of manufacturability indices related to viscosity and thermostability to rank high‐concentration mAb formulation conditions in terms of their ease of manufacture. This is illustrated by analyzing published high‐throughput biophysical screening data that explores the influence of different formulation conditions (pH, ions, and excipients) on the solution viscosity and product thermostability. A decision tree classification method, CART (Classification and Regression Tree) is used to identify the critical formulation conditions that influence the viscosity and thermostability. In this work, three different multi‐criteria data analysis frameworks were investigated to derive manufacturability indices from analysis of the stress maps and the process conditions experienced in the final UF/DF step. Polynomial regression techniques were used to transform the experimental data into a set of stress maps that show viscosity and thermostability as functions of the formulation conditions. A mathematical filtrate flux model was used to capture the time profiles of protein concentration and flux decay behavior during UF/DF. Multi‐criteria decision‐making analysis was used to identify the optimal formulation conditions that minimize the potential for both viscosity and aggregation issues during UF/DF. Biotechnol. Bioeng. 2017;114: 2043–2056. © 2017 The Authors. Biotechnology and Bioengineering Published by Wiley Perodicals, Inc.

[1]  A. Zydney,et al.  A Combined Pore Blockage and Cake Filtration Model for Protein Fouling during Microfiltration. , 2000, Journal of colloid and interface science.

[2]  Feng He,et al.  Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis. , 2011, Journal of pharmaceutical sciences.

[3]  S J Prestrelski,et al.  Precipitation of proteins in supercritical carbon dioxide. , 1996, Journal of pharmaceutical sciences.

[4]  Feng He,et al.  Effect of Sugar Molecules on the Viscosity of High Concentration Monoclonal Antibody Solutions , 2011, Pharmaceutical Research.

[5]  A. Vermeer,et al.  The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. , 2000, Biophysical journal.

[6]  Deborah S. Goldberg,et al.  Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability. , 2011, Journal of pharmaceutical sciences.

[7]  Sandeep Yadav,et al.  Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. , 2010, Journal of pharmaceutical sciences.

[8]  C. Yu,et al.  The role of proline in the prevention of aggregation during protein folding in vitro , 1998, Biochemistry and molecular biology international.

[9]  Linda O Narhi,et al.  High throughput thermostability screening of monoclonal antibody formulations. , 2010, Journal of pharmaceutical sciences.

[10]  Thomas W Patapoff,et al.  Polysorbate 20 prevents the precipitation of a monoclonal antibody during shear. , 2009, Pharmaceutical development and technology.

[11]  R. Kelley,et al.  Molecular Assessment of Monoclonal Antibody-Based Therapeutics Enabling Lead Selection for Clinical Development , 2015 .

[12]  Steven J Shire,et al.  Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. , 2005, Journal of pharmaceutical sciences.

[13]  D. Brems,et al.  Inverse Relationship of Protein Concentration and Aggregation , 2002, Pharmaceutical Research.

[14]  Sandeep Yadav,et al.  Specific interactions in high concentration antibody solutions resulting in high viscosity. , 2010, Journal of pharmaceutical sciences.

[15]  S. D. Webb,et al.  Freezing bulk-scale biopharmaceuticals using common techniques: and the magnitude of freeze-concentration , 2002 .

[16]  Steven J Shire,et al.  Formulation and manufacturability of biologics. , 2009, Current opinion in biotechnology.

[17]  Suzanne S. Farid,et al.  Data mining for rapid prediction of facility fit and debottlenecking of biomanufacturing facilities. , 2014, Journal of biotechnology.

[18]  Suzanne S Farid,et al.  Fed‐batch and perfusion culture processes: Economic, environmental, and operational feasibility under uncertainty , 2013, Biotechnology and bioengineering.

[19]  Jennifer R Litowski,et al.  High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. , 2010, Analytical biochemistry.

[20]  Wei-Yin Loh,et al.  Classification and regression trees , 2011, WIREs Data Mining Knowl. Discov..

[21]  Oliver Kaltenbrunner,et al.  Recovery modeling of tangential flow systems , 2012, Biotechnology and bioengineering.

[22]  Steven J Shire,et al.  Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity. , 2008, Journal of pharmaceutical sciences.

[24]  B. Turczyński,et al.  A comparative study on viscosity of human, bovine and pig IgG immunoglobulins in aqueous solutions. , 1999, International journal of biological macromolecules.

[25]  A. Vermeer,et al.  The unfolding/denaturation of immunogammaglobulin of isotype 2b and its F(ab) and F(c) fragments. , 2000, Biophysical journal.

[26]  M. Shameem,et al.  Commercial therapeutic protein drug products , 2012 .

[27]  Brian Hubbard,et al.  Downstream processing of monoclonal antibodies--application of platform approaches. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[28]  Steven J Shire,et al.  Challenges in the development of high protein concentration formulations. , 2004, Journal of pharmaceutical sciences.

[29]  Walter J. Freeman,et al.  Classification of EEG Spatial Patterns with a Tree-Structured Methodology: CART , 1986, IEEE Transactions on Biomedical Engineering.

[30]  T. Arakawa,et al.  Theory of protein solubility. , 1985, Methods in enzymology.

[31]  Steven J. Shire,et al.  Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies , 2004 .

[32]  Linda O Narhi,et al.  High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations. , 2011, Journal of pharmaceutical sciences.